Belinostat

Product Description

Belinostat is a potent pan-HDAC inhibitor (IC₅₀ = 28 nM). Dose-dependently reduces tumor volume in a rat model of glioblastoma and induces 70% and 28% apoptosis in LN-229 and LN-18 glioma cell lines (IC₅₀ values are 210 nM and 300 nM respectively). In H358 cells, Belinostat dose-dependently reduces cell viability and upregulates amino acids and metabolites of the TCA and urea cycle. Also potently inhibits C4 release from stem cell-derived astrocytes and shows antidepressant activity. Belinostat is brain penetrant.

Solubility

Preparing Stock Solutions for Belinostat

The following data is based on the product molecular weight 318.35

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	3.14 mL	15.71 mL	31.41 mL
5 mM	0.63 mL	3.14 mL	6.28 mL
10 mM	0.31 mL	1.57 mL	3.14 mL
50 mM	0.06 mL	0.31 mL	0.63 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Gurbani Assessing treatment response of glioblastoma to an HDAC inhibitor using whole-brain spectroscopic MRI. Tomography 2019 PMID: 30854442
• Rapino Small-molecule screen reveals pathways that regulate C4 secretion in stem cell-derived astrocytes. Stem Cell Reports 2023 PMID: 36563689
• Kusaczuk Molecular and cellular effects of a novel hydroxamate-based HDAC inhibitor - belinostat - in glioblastoma cell lines: a preliminary report. Invest.New Drugs 2016 PMID: 27468826
• Peter Histone deacetylase inhibitor belinostat regulates metabolic reprogramming in killing KRAS-mutant human lung cancer cells. Mol.Carcinog. 2022 PMID: 37144836
• Finn Novel sulfonamide derivatives as inhibitors of histone deacetylase. Helv.Chim.Acta